Venture Capital news from FierceBiotech
NewsNanoBio looks for Big Pharma partners
Crain's Detroit Business is reporting that NanoBio--a 2008 Fierce 15 company--is close to announcing an $11 Read more...
ProteoStasis secures $45M in first round
Despite a lack of office space or even a complete research team, newcomer ProteoStasis Therapeutics has secured a whopping $45 million in Series A financing. Investors include Boston-based HealthCare Read more...
Anthera garners $19M in new venture funds
Anthera Pharmaceuticals has completed a $19 million venture round and plans to use the funds to advance its work on anti-inflammatory drugs. New investors Caxton Advantage Life Sciences Fund and HBM Read more...
Follica quickly lans $11M second round
Just seven months after raising $5.5 million in its Series A round, Boston-based Follica announced that it Read more...
InterWest closes $650M fund
Life science VC firm InterWest Partners has closed a $650 million fund. The money will be invested in emerging life sciences and information technology investments. The group aims to invest in 25 to Read more...
Bill offers small developers shot at R&D funds
Biotech companies majority-owned by venture groups would once again have a shot at some $2 billion in Small Business Innovation Research awards under compromise legislation advanced in the U.S. Read more...
ESBATech rounds up $22M in second round
Switzerland's ESBATech has garnered $22 million in an extended Series B round. The money goes to expand its pipeline and advance the biotech's work developing antibody fragment therapies. SV Life Read more...
Tetraphase raises $15M for antibiotic work
Massachusetts-based Tetraphase Pharmaceuticals has closed the second tranche of its $25 million Series A financing. The $15 million tranche was funded by existing investors, including Mediphase Read more...
Dimera needs $40M to survive, mount trial
The tiny, Portland-based developer Dimera tells the local Business Journal that the company needs to raise $40 million in order to survive. Backed by the president's personal funds and grants from Read more...
Versant closes $500M fund for early-stage research
Versant Ventures has pulled together $500 million to fund life science companies. The investment group says it will target approximately 30-35 medical device, biotech, and pharmaceutical investments Read more...
| Press ReleasesResolvyx Pharmaceuticals Raises $25 Million in Series B Financing Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing 4/22/2008 BEDFORD, Mass. -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has Read more... Venture Capital Investment Declines in Q1 2008 According to the MoneyTree Report Venture Capital Investment Declines in Q1 2008 According to the MoneyTree Report Life Sciences, Semiconductors Have Strong Quarter WASHINGTON, DC--(Marketwire - April 21, 2008) - Venture capitalists Read more... PRESS RELEASE: PregLem Announces CHF 36 Million Series B Funding PregLem Announces CHF 36 Million Series B Funding GENEVA -- PregLem, a Swiss specialty biopharmaceutical company focused on the development and commercialization of innovative therapeutic compounds Read more... PRESS RELEASE: BioVex Closes Second Round of Series E Financing BioVex Closes Second Round of Series E Financing Second and Final Close Completes $35 Million Financing Woburn, MA, November 15 2007 – BioVex Inc, a clinical stage company developing new Read more... PRESS RELEASE: Zosano Pharma Announces Funding Close Totaling $90 Million Zosano Pharma Announces Funding Close Totaling $90 Million FREMONT, Calif. -- Zosano Pharma, Inc., an emerging specialty pharmaceutical company focused on developing better pharmaceutical products Read more... |
Get more Venture Capital coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets